166 related articles for article (PubMed ID: 20525654)
1. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy.
Crouser ED; Lozanski G; Fox CC; Hauswirth DW; Raveendran R; Julian MW
Chest; 2010 Jun; 137(6):1432-5. PubMed ID: 20525654
[TBL] [Abstract][Full Text] [Related]
2. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations.
Sweiss NJ; Salloum R; Gandhi S; Alegre ML; Sawaqed R; Badaracco M; Pursell K; Pitrak D; Baughman RP; Moller DR; Garcia JG; Niewold TB
PLoS One; 2010 Feb; 5(2):e9088. PubMed ID: 20140091
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
4. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Russell E; Luk F; Manocha S; Ho T; O'Connor C; Hussain H
Semin Arthritis Rheum; 2013 Aug; 43(1):119-24. PubMed ID: 23332903
[TBL] [Abstract][Full Text] [Related]
5. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
Baughman RP; Iannuzzi M
BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
[TBL] [Abstract][Full Text] [Related]
6. CD4
Popescu I; Snyder ME; Iasella CJ; Hannan SJ; Koshy R; Burke R; Das A; Brown MJ; Lyons EJ; Lieber SC; Chen X; Sembrat JC; Bhatt P; Deng E; An X; Linstrum K; Kitsios G; Konstantinidis I; Saul M; Kass DJ; Alder JK; Chen BB; Lendermon EA; Kilaru S; Johnson B; Pilewski JM; Kiss JE; Wells AH; Morris A; McVerry BJ; McMahon DK; Triulzi DJ; Chen K; Sanchez PG; McDyer JF
Am J Respir Crit Care Med; 2022 Jun; 205(12):1403-1418. PubMed ID: 35348444
[No Abstract] [Full Text] [Related]
7. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
[TBL] [Abstract][Full Text] [Related]
8. [TNFα blocking agents and sarcoidosis: an update].
Toussirot E; Pertuiset E
Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for refractory sarcoidosis.
Baughman RP; Lower EE
Sarcoidosis Vasc Diffuse Lung Dis; 2001 Mar; 18(1):70-4. PubMed ID: 11354550
[TBL] [Abstract][Full Text] [Related]
10. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.
Yee AM; Pochapin MB
Ann Intern Med; 2001 Jul; 135(1):27-31. PubMed ID: 11434729
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
Pritchard C; Nadarajah K
Ann Rheum Dis; 2004 Mar; 63(3):318-20. PubMed ID: 14962969
[TBL] [Abstract][Full Text] [Related]
12. [Nasosinusal and cervical sarcoidosis: a case series of three patients and literature review].
Hermet M; le Guenno G; Rieu V; Philippe P; Ruivard M
Rev Med Interne; 2012 Jan; 33(1):46-9. PubMed ID: 21601318
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Baughman RP; Lower EE; Drent M
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
[TBL] [Abstract][Full Text] [Related]
14. Therapy with infliximab decreases the CD4+CD28- T cell compartment in peripheral blood in patients with rheumatoid arthritis.
Pawlik A; Ostanek L; Brzosko I; Brzosko M; Masiuk M; Machalinski B; Szklarz BG
Rheumatol Int; 2004 Nov; 24(6):351-4. PubMed ID: 14504910
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy.
Menon Y; Cucurull E; Reisin E; Espinoza LR
Am J Med Sci; 2004 Sep; 328(3):173-5. PubMed ID: 15367877
[TBL] [Abstract][Full Text] [Related]
16. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
17. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
[TBL] [Abstract][Full Text] [Related]
18. Refractory multisystem sarcoidosis responding to infliximab therapy.
Croft AP; Situnayake D; Khair O; Giovanni G; Carruthers D; Sivaguru A; Gordon C
Clin Rheumatol; 2012 Jun; 31(6):1013-8. PubMed ID: 22249374
[TBL] [Abstract][Full Text] [Related]
19. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
[TBL] [Abstract][Full Text] [Related]
20. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
